In results the mean fall in HAMD-24 scores between groups was comparable till 4 weeks. Thereafter, at 8 weeks the mean fall in HAMD-24 score was significantly greater in duloxetine group (p value < 0.05). At 16 weeks the mean fall was highly significant (p value < 0.01) in duloxetine group. Thirty percent patients in duloxetine group achieved remission in comparison to none in fluoxetine group. None of the patient, in any group, reported relapse. Adverse effects were mild to moderate in severity.In conclusion duloxetine has a better pharmacological profile over fluoxetine in terms of efficacy and safety.
INTRODUCTION
Major depressive disorder (MDD) represents one of the most serious conditions encountered in clinical practice affecting 340 million people globally [1] . It is currently estimated to be the fourth leading cause of disability adjusted life years (DALY) in all age groups. Selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for moderate to severe depression [2] . However, studies have shown that up to half of all depressed patients fail to respond to SSRIs treatment. Thus there exists need for alternatives with multiple mechanisms along with avoidance of unwanted effects of tricyclic antidepressants (TCA) [3] .
Duloxetine, a newer antidepressant which belongs to selective serotonin nor-epinephrine reuptake inhibitor (SSNRI) group, has been approved for MDD [4] . In double blind, placebo controlled multicentre, randomized, 9 weeks trials Gartlehner et al. [5] and Detke et al. [6] concluded that, for treatment of MDD Duloxetine is safe and effective. In 8 weeks, fluoxetine comparator trial, remission rates were high in duloxetine group, but not statistically significantly than fluoxetine group [7] . For long term treatment of MDD duloxetine has been shown to be effective in 52 weeks non-comparator open label multicentre trial [8] .
As previous studies indicate that duloxetine may have some advantages in MDD, however there are limited numbers of studies which assess SSRIs as active comparators [9] . These studies are lacking with data's either duo to of short duration of study or duo to of lack of standard comparator. Therefore the current study was planned to compare remission rate, relapse rate and safety of oral duloxetine (SSNRI) with fluoxetine (SSRI) in 16 weeks comparative study.
Pharmacology in collaboration with the Department of Psychiatry, Lady Hardinge Medical College and associated Smt. Sucheta Kriplani (SSK) Hospital, New Delhi. Sixty six Patients, aged between 18 and 65 years with either sex, presenting with MDD, as per ICD-10 DCR criteria [10] , on an outpatient basis, were included after obtaining an informed consent. The study protocol was approved by Institution Ethics Committee. Baseline disease severity was defined by patients' scores on the Hamilton Rating Scale for Depression-24 items (HAMD-24) [11] . Exclusion criteria were history of psychosis or bipolar disorder, substance abuse disorder, intake of psychoactive medication during past two weeks. Patients with serious medical illness, serious suicidal risk requiring hospitalization and pregnant or lactating women were also excluded from study. A complete workup was done for all patients with respect to history, baseline investigations (weight, blood pressure, hemoglobin, complete blood count, blood sugar, serum electrolyte, kidney and liver function test) and clinical examinations.
All patients were randomly assigned to Fluoxetine 20-60 mg per oral (FLX) and Duloxetine 40-60 mg per oral (DLX) group. Both the study drugs were administered daily for 16 weeks and dose was titrated as per the need of patient.
CLINICAL ASSESSMENT OF PATIENTS
Clinical response of the patients was assessed at baseline (0 week), 1 week, 2 week, 4 week, 8 week and 16 week by using HAMD-24 scale. Improvement in HAMD-24 score from baseline was used as the primary efficacy measure to assess remission and relapse. Remission was defined as a total score on HAMD-24 of ≤ 7 and relapse was defined as an episode of MDD that occurs within 6 months after either response or remission [12] .
SAFETY PROFILE
The patients were monitored for any adverse drug effects during the course of study. The patients as well as the informants were asked in detail about any adverse drug effects the course of treatment on each visit.
STATISTICAL ANALYSIS
Baseline and end-point HAMD-24 scores were compared within groups using the paired student's t-test. Unpaired student's t-test was used for comparison of parameters between two study groups. Safety profile and response rate were compared between two treatment groups by Fisher's exact test. P value of < 0.05 was taken to be significant.
RESULTS
A total of 66 patients enrolled, out of which 60 completed the study. Biosocial and demographic characteristics of patients were comparable ( Table 1) . Baseline bodyweight, pulse rate, blood pressure and biochemical parameters in both the groups were matching. On completion of treatment there were reduction in mean body weight in both groups which was statistically significant (P < 0.05). In FLX group bodyweight reduced from 59.27 ± 1.93 kg to 58.84 ± 1.84 kg (p value < 0.05) while in DLX group body weight reduced from 57.37 ± 1.53 kg to 56.77 ± 1.52 kg after 16 weeks. In DLX group blood sugar levels also reduced significantly (p value < 0.05) from 104.60 ± 2.33 mg/dl to 102.73 ± 2.03 mg/dl while there was statistically significant rise in hemoglobin at end of the study. The mean values of other parameters after16 week were comparable within as well as between the both groups.
CLINICAL RESPONSE (EFFICACY)
Baseline HAMD-24 scores in FLX and DLX groups were 17.46 ± 0.13 and 17.70 ± 0.08 respectively ( scores were recorded at 2 week, 4 week, 8 week and 16 week respectively. On comparing FLX and DLX groups the mean fall in HAMD-24 scores were comparable till 4 weeks. Thereafter, at 8 weeks the mean fall in HAMD score was significantly greater in DLX group i.e. 11.10 ± 0.24 (p < 0.05). At 16 weeks the mean fall was highly significant (p value < 0.01) in DLX group vs. the FLX group ( Table  2) .
REMISSION AND RELAPSE
In FLX group there was no remission till 16 weeks of treatment, where as in DLX group 9 patients remitted with in 16 weeks. None of the patient, in any group, reported relapse of any sign or symptoms of MDD during study period.
ADVERSE DRUG EVENTS
A total of 99 adverse events were recorded in FLX group as compared to 37 adverse events in DLX group. Nausea was frequent adverse events in FLX group as compared to DLX. Insomnia, sweating and diarrhoea were the other frequent adverse events observed in FLX group. Nausea, dry mouth, diarrhoea and fatigue constituted the frequent adverse events in DLX group. These adverse effects were mild to moderate and there were no serious adverse event in both the groups ( Table 3) .
DISCUSSION
After one week of treatment, overall fall in HAMD-24 score was greater in DLX group than FLX group. In DLX (20 mg twice daily) group, reduction in HAMD-24 score at 8 and 16 weeks from baseline value was -6.6 and -9.64 whereas in FLX (20 mg once daily) fall was -5.4 and -7.5. Similarly, Goldstein et al. (2002) reported a higher fall in HAMD scores with duloxetine (n-Number of total adverse events) (-9.73) than with fluoxetine (-7.75) or placebo (-6.6) in an 8 week study [7] . Hudson et al. (2007) reported higher reduction in HAMD-24 scores at 12 weeks with duloxetine (60 mg/day) [1] . The early and higher response rate may be due to higher dose of duloxetine. In present 16 week study and previous short period studies, duloxetine shown to have better efficacy than SSRIs, which may be due to its combined effects on both the serotonin and norepinephrine systems. This dual mechanism makes duloxetine potent (4.5 times) and to act faster than SSRIs [1, 13] . Also, when compared with other dual action antidepressants like venlafaxine, duloxetine appears to be more balanced inhibitor of serotonin and norepinephrine reuptake. Further, experimental data predicted that dual serotonin and norepinephrine exert analgesic effects via descending pain pathways; therefore duloxetine is more suitable in depression with somatic symptoms [1] . In this study response rate from one week onward was 100% in both the groups and remission rate was 33% and 0% in DLX and FLX group respectively at end of 16 weeks. Goldstein D.J. et al. (2002) also reported response and remission rate of 64% and 56% respectively for du-loxetine (20 mg twice daily), compared with 52% and 30% for fluoxetine (20 mg once daily) and 48% and 32% for placebo, indicates superior efficacy of duloxetine over Fluoxetine [7] . In another 8 weeks trial, Goldstein DJ (2004) showed response and remission rates were 54% and 37% for duloxetine (40 mg once daily), 60% and 58% for duloxetine (80 mg) in comparison to Openly accessible at http://www.scirp.org/journal/HEALTH/ 50% and 34% for paroxetine (20 mg once daily) and 30% and 28% for placebo [14] . In a metanalysis by Jennifer et al. (2006) the remission rate was found to be superior for duloxetine as compared to SSRIs (43% vs. 38%). Also when alternative definition of remission (MADRS score ≤ 12) was used, duloxetine was found to be sig-nificantly better than SSRIs [9] .
In both groups there was no relapse till 16 weeks. Although the study duration of 4 months is not sufficient to comment upon relapse rate but as per definition of relapse there was no reoccurrence of sign and symptoms after response has been establish in both groups. Relapse rate for the fluoxetine group was found to be 35.2% after 6 month and 45.9% after 1 year of treatment [15] . In randomized double blind, multicenter, placebo controlled, parallel group study, David G.P. et al. (2006) showed that duloxetine (60 mg once daily) was effective in the prevention of relapse of MDD during continuation of treatment [16] . Geddes et al. (2003) had concluded on systemic review of 31 antidepressant trials that continuing with antidepressant reduced the odds of depressive relapse by 70% compared to placebo. This suggests continued antidepressant treatment has ability to reduce the chances of depressive relapse [17] .
Duloxetine has better adverse effect profile. In DLX group 30% of patients experienced adverse events in which nausea (26.7%) and dry mouth (16.7%) were principally reported. Other adverse events were diarrhea, fatigue, dizziness and vomiting. Sharma A. et al. (2000) have also reported similar adverse effect profile for duloxetine [18] . As a reuptake inhibitor of norepinephrine, duloxetine has been found to be associated with mean increase in heart rate as well as blood pressure (less than 2 mmHg) [8] . No such cardiovascular adverse effect was observed in this study .In FLX group, patients mainly reported nausea (56.6%) and insomnia (50%) followed by other adverse events which includes sweating, diarrhea, anorexia, vomiting, dry mouth and anxiety. In a study of 6 months, Zajecka et al. (1999) have reported similar adverse events [19] .
Ejaculation delayed was reported by 3 male patients (10%) in FLX group. Similarly Harman J.B. et al. (1990) also reported frequent sexual dysfunction with Fluoxetine [20] . Comparatively in DLX group, there was no sexual dysfunction occurred in any patients although it has been reported by Detke M.J. et al. (2002) [21] .
All the adverse effects during study period were mild to moderate severity. On the WHO casualty assessment scale they were classified as possible. Favorable adverse effect profile of duloxetine may be because of its less affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate and GABA receptors [1] .
CONCLUSIONS
In this comparative study duloxetine was found to be more efficacious than fluoxetine in reducing HAMD-24 score in 16 weeks as well as found to have better adverse effect profile than fluoxetine. This suggests that for treatment of MDD duloxetine is better option over fluoxetine.
